Authors

Latest:

Dr. Gandhi Discusses the Role of Alectinib in ALK+ Lung Cancer

Leena Gandhi, MD, PhD, director of the Thoracic Medical Oncology Program at NYU Langone School of Medicine, discusses the role of alectinib (Alecensa) in patients with ALK-positive non-small cell lung cancer (NSCLC).

Lei Chen, MD, PhD

Latest:

Treatment Patterns of Metastatic Triple-Negative Breast Cancer in US Community Practice Settings

First-line treatment patterns for metastatic triple-negative breast cancer are diverse, reflecting a lack of consensus and an unmet need for standardized therapy.

Leif Bergsagel, MD

Latest:

Dr. Bergsagel on Treatment Options for Relapsed/Refractory Myeloma

Leif Bergsagel, MD, consultant and professor of medicine, Division of Hematology/Oncology, Mayo Clinic, discusses treatment options for patients with relapsed/refractory multiple myeloma.

Leigh A. Neumayer, MD

Latest:

Dr. Neumayer Discusses the POWER PIINC Trial

Leigh A. Neumayer, MD, discusses the POWER PIINC trial, a study to measure the preoperative window of endocrine therapy.

Leigha Senter, MS, LGC

Latest:

Biomarker Research in Ovarian Cancer

Leigha Senter, MS, LGC, discusses ongoing biomarker research efforts in ovarian cancer.

Leisha A. Emens, MD, PhD

Latest:

Dr. Emens on Immune-Related Adverse Events in Ovarian Cancer

Leisha A. Emens, MD, PhD, discusses the incidence and treatment of immune-related adverse events in ovarian cancer.

Leo Gordon, MD, Northwestern Memorial Hospital

Leo I. Gordon, MD

Latest:

Dr Gordon on Managing Toxicities Associated With Liso-Cel in MCL

Leo I. Gordon, MD, discusses toxicities associated with lisocabtagene maraleucel in patients with mantle cell lymphoma.

Leo I. Gordon, MD, FACP, Robert H. Lurie Comprehensive Cancer Center

Leo I. Gordon, MD, Robert H. Lurie Comprehensive Cancer Center

Latest:

Practice Patterns and Real Use of Epcoritamab and Glofitamab

A panel of experts discuss the role of odronextamab.

Leonard G. Gomella, MD

Latest:

Dr. Gomella on Novel Biomarker Research in Prostate Cancer

Leonard G. Gomella, MD, discusses ongoing studies evaluating novel biomarkers in prostate cancer.

Leonard G. Gomella, MD, Jefferson Kimmel

Leonard Gomella, MD

Latest:

Dr. Gomella on the Challenges of Optimizing PSA as a Biomarker in Prostate Cancer

Leonard G. Gomella, MD, discusses the challenges of optimizing prostate-specific antigen as a biomarker in prostate cancer.

Leonard S. Sender

Leonard Saltz, MD

Latest:

Dr. Saltz Discusses FOLFIRINOX in Colorectal Cancer

Leonard Saltz, MD, executive director for Clinical Value & Sustainability, head, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center, discusses the option of FOLFIRINOX for the treatment of patients with metastatic colorectal cancer.

Leonid Shunyakov, MD

Latest:

Dr. Shunyakov on the Impact of Genomics on Personalized Therapy in Oncology

Leonid Shunyakov, MD, hematologist/oncologist, Central Care Cancer Center, discusses how genomics have impacted personalized therapy in oncology.

Leonie de Best, MSc2

Latest:

Leonie de Best on Validation of EMC92/SKY92 Signature in Myeloma

Leonie de Best, MSc2, chief operating officer, SkylineDX, discusses the HOVON-87/NMSG-18 study, which demonstrated the validation of the EMC92/SKY92 signature for elderly patients with newly diagnosed multiple myeloma.

Leora Horn, MD

Latest:

Dr. Horn on Updated IMpower133 Data in Small Cell Lung Cancer

Leora Horn, MD, MSc, discusses data from an updated analysis of the phase 3 IMpower133 trial, which examined the first-line combination of atezolizumab (Tecentriq), carboplatin, and etoposide in small cell lung cancer.

Leora Horn, MD, MSc

Latest:

Dr. Horn on the Role of Mobocertinib in NSCLC

Leora Horn, MD, MSc, FRCPC, discusses the role of mobocertinib in patients with non–small cell lung cancer.

Leora Horn, MD, MSc, FRCPC, Vanderbilt University Medical Center